{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:38:41Z","timestamp":1793104721294,"version":"4.5.0"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jhep.2026.08.028","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:34:10Z","timestamp":1790642050000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy"],"prefix":"10.1016","author":[{"given":"Frank","family":"Tacke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent Wai-Sun","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Bugianesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Francque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Zelber-Sagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Caussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Roden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Gastaldelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Ciudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2026.08.028_bib1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Associaton for the Study of the Liver","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2026.08.028_bib3","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction\u2013associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"New Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.jhep.2026.08.028_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/dom.70545","volume":"28","author":"Chen","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2026.08.028_bib5","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/S0140-6736(26)00138-8","article-title":"Implementing sustainable liver health in Europe: a second EASL-Lancet Commission","volume":"407","author":"Karlsen","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.08.028_bib6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S2468-1253(25)00323-1","article-title":"Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart-liver co-management","volume":"11","author":"Zhou","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib7","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.cgh.2026.03.030","article-title":"Updated global consensus recommendations for risk stratification, treatment initiation, and response monitoring in metabolic dysfunction-associated steatotic liver disease","volume":"24","author":"Younossi","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jhep.2018.10.011","article-title":"Clinical Practice Guidelines of the European Association for the study of the liver \u2013 advancing methodology but preserving practicability","volume":"70","author":"Cornberg","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib9","author":"Oxford Centre for Evidence-Based Medicine"},{"key":"10.1016\/j.jhep.2026.08.028_bib10","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jhep.2025.01.014","article-title":"Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease","volume":"83","author":"Yip","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib11","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/gutjnl-2025-337506","article-title":"Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes","volume":"75","author":"Chen","year":"2026","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2026.08.028_bib12","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3350\/cmh.2025.0888","article-title":"Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement","volume":"32","author":"Rabbat","year":"2026","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib13","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1038\/s41591-026-04496-2","article-title":"Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study","volume":"32","author":"Pavlides","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2026.08.028_bib14","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.jhep.2021.04.044","article-title":"Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis","volume":"75","author":"Selvaraj","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib15","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis","volume":"71","author":"M\u00f3zes","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2026.08.028_bib16","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.3350\/cmh.2024.0392","article-title":"Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"30","author":"Chon","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib17","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","article-title":"Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study","volume":"8","author":"Vali","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib18","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.08.028_bib19","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease","volume":"385","author":"Sanyal","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2026.08.028_bib20","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2024.05.008","article-title":"Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD","volume":"81","author":"Gawrieh","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib21","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","article-title":"Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis","volume":"8","author":"M\u00f3zes","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib22","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1053\/j.gastro.2022.06.073","article-title":"Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants","volume":"163","author":"Ajmera","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.08.028_bib23","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/hep.32204","article-title":"Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis","volume":"75","author":"Sanyal","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.08.028_bib24","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000931","article-title":"Multi-threshold analysis of the ELF test versus histology for prognostication of disease progression and regression in MASH","volume":"10","author":"Gee","year":"2026","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2026.08.028_bib25","article-title":"Enhanced liver fibrosis (ELF) score predicts hepatic decompensation and mortality","volume":"6","author":"Pearson","year":"2024","journal-title":"JHEPReport"},{"key":"10.1016\/j.jhep.2026.08.028_bib26","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jama.2024.1447","article-title":"Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease","volume":"331","author":"Lin","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2026.08.028_bib27","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","article-title":"Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography","volume":"150","author":"Imajo","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.08.028_bib28","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","article-title":"Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"152","author":"Park","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.08.028_bib29","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII - renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib30","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jhep.2025.10.014","article-title":"Refining the Baveno VII criteria for clinically significant portal hypertension: an individual patient data meta-analysis","volume":"84","author":"Ba\u00f1ares","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3350\/cmh.2019.0001n","article-title":"Application of transient elastography in nonalcoholic fatty liver disease","volume":"26","author":"Zhang","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/jgh.14311","article-title":"Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness","volume":"34","author":"Chow","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib33","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.ultrasmedbio.2024.03.013","article-title":"WFUMB guideline\/guidance on liver multiparametric ultrasound: part 1. update to 2018 guidelines on liver ultrasound elastography","volume":"50","author":"Ferraioli","year":"2024","journal-title":"Ultrasound Med Biol"},{"key":"10.1016\/j.jhep.2026.08.028_bib34","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/apt.17734","article-title":"Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis","volume":"59","author":"Harrison","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.08.028_bib35","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/apt.18331","article-title":"Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial","volume":"60","author":"Newsome","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.08.028_bib36","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","article-title":"Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","volume":"407","author":"Nauck","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.08.028_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2025.108811","article-title":"Insights into the results of Resmetirom trials: can a thyroid hormone receptor agonist be the holy grail of MASH therapy?","volume":"268","author":"Arvanitakis","year":"2025","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.08.028_bib38","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/apt.70382","article-title":"Effects of resmetirom on metabolic-dysfunction associated steatohepatitis in patients with weight loss and\/or diabetes taking glucagon-like peptide-1 receptor agonists and other diabetes therapies: a secondary analysis of the MAESTRO - NASH trial","volume":"62","author":"Noureddin","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.08.028_bib39","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s12020-024-04085-8","article-title":"Adiponectin may play a crucial role in the metabolic effects of GLP-1RAs treatment in patients with Type 2 Diabetes Mellitus: a preliminary longitudinal study","volume":"87","author":"Al Refaie","year":"2025","journal-title":"Endocrine"},{"key":"10.1016\/j.jhep.2026.08.028_bib40","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.70218","article-title":"Comparative efficacy and safety of resmetirom and efruxifermin for metabolic dysfunction-associated steatohepatitis: a network meta-analysis of randomized controlled trials","volume":"9","author":"Jaber","year":"2026","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.jhep.2026.08.028_bib41","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/gutjnl-2025-337431","article-title":"Combination therapies for metabolic dysfunction-associated steatohepatitis: challenges and opportunities","volume":"75","author":"Zhou","year":"2026","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2026.08.028_bib42","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1038\/s41591-025-03722-7","article-title":"TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial","volume":"31","author":"Noureddin","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2026.08.028_bib43","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jhep.2024.10.018","article-title":"Thyroid hormone receptor-\u03b2 analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)","volume":"82","author":"Ratziu","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib44","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2023.03.014","article-title":"A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials","volume":"79","author":"Pais","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib45","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jhep.2020.04.030","article-title":"Standardisation of diet and exercise in clinical trials of NAFLD-NASH: recommendations from the liver forum","volume":"73","author":"Glass","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib46","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis","volume":"73","author":"Vali","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib47","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.08.028_bib48","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2026.08.028_bib49","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jhep.2026.08.028_bib50","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Stevens","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.jhep.2026.08.028_bib51","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib52","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S2468-1253(26)00123-8","article-title":"Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a dose-ranging, placebo-controlled phase 2 trial","volume":"11","author":"Loomba","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib53","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.08.028_bib54","article-title":"Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: a systematic review","volume":"41","author":"Sanyal","year":"2024","journal-title":"Am Heart J Plus: Cardiol Res Pract"},{"key":"10.1016\/j.jhep.2026.08.028_bib55","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2025.03.001","article-title":"Cause-specific mortality in 13,099 patients with metabolic dysfunction-associated steatotic liver disease in Sweden","volume":"83","author":"Issa","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib56","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1186\/s12916-025-04486-0","article-title":"The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and trial sequential analysis","volume":"23","author":"Sillassen","year":"2025","journal-title":"BMC Med"},{"key":"10.1016\/j.jhep.2026.08.028_bib57","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jhep.2026.08.028_bib58","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","article-title":"Global consensus recommendations for metabolic dysfunction-associated steatotic liver disease and steatohepatitis","volume":"169","author":"Younossi","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.08.028_bib59","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1097\/TP.0000000000005361","article-title":"Impact of glucagon-like peptide-1 receptor agonists on metabolic health in liver transplant recipients","volume":"109","author":"Yakubu","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2026.08.028_bib60","series-title":"Assessment report -Rezdiffra","author":"Committee for Medicinal Products for Human Use (CHMP)","year":"2025"},{"key":"10.1016\/j.jhep.2026.08.028_bib61","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1016\/j.cgh.2023.03.042","article-title":"Noninvasive assessment of liver fibrosis in NAFLD","volume":"21","author":"Sanyal","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib62","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"19","author":"Stine","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102310","article-title":"FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"66","author":"Wai-Sun Wong","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jhep.2026.08.028_bib64","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13841","article-title":"Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity","volume":"26","author":"Mechanick","year":"2025","journal-title":"Obes Rev"},{"key":"10.1016\/j.jhep.2026.08.028_bib65","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society","volume":"15","author":"Mozaffarian","year":"2025","journal-title":"Obes Pillars"},{"key":"10.1016\/j.jhep.2026.08.028_bib66","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jhep.2021.11.006","article-title":"Effect of sarcopenia on survival in patients with cirrhosis: a meta-analysis","volume":"76","author":"Tantai","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib67","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/jcsm.12039","article-title":"Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis","volume":"7","author":"Montano-Loza","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.jhep.2026.08.028_bib68","article-title":"Contribution of sarcopenia and physical inactivity to mortality in people with non-alcoholic fatty liver disease","volume":"2","author":"Golabi","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2026.08.028_bib69","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/ueg2.12280","article-title":"European guideline on obesity care in patients with gastrointestinal and liver diseases - joint European Society for Clinical Nutrition and Metabolism\/United European Gastroenterology guideline","volume":"10","author":"Bischoff","year":"2022","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhep.2026.08.028_bib70","article-title":"Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: an expert consensus statement using a modified Delphi approach","volume":"17","author":"Sievenpiper","year":"2026","journal-title":"Obes Pillars"},{"key":"10.1016\/j.jhep.2026.08.028_bib71","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s13668-024-00548-6","article-title":"Nutritional considerations during major weight loss therapy: focus on optimal protein and a low-carbohydrate dietary pattern","volume":"13","author":"Volek","year":"2024","journal-title":"Curr Nutr Rep"},{"key":"10.1016\/j.jhep.2026.08.028_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.advnut.2025.100522","article-title":"Nutritional challenges of incretin-based obesity management medications: implications for clinical practice","volume":"16","author":"Ben-Porat","year":"2025","journal-title":"Adv Nutr"},{"key":"10.1016\/j.jhep.2026.08.028_bib73","first-page":"SP226","article-title":"CHAPTER 2. Clinical nutrition guideline for overweight and obese adults with type 2 diabetes (T2D) or prediabetes, or those at high risk for developing T2D","volume":"24","author":"Hamdy","year":"2018","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jhep.2026.08.028_bib74","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jamainternmed.2025.1133","article-title":"Am taking a GLP-1 weight-loss medication-what should i know?","volume":"185","author":"Mehrtash","year":"2025","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jhep.2026.08.028_bib75","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3390\/nu10040423","article-title":"Resistance training prevents muscle loss induced by caloric restriction in obese elderly individuals: a systematic review and meta-analysis","volume":"10","author":"Sardeli","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.jhep.2026.08.028_bib76","doi-asserted-by":"crossref","DOI":"10.1111\/cob.70070","article-title":"Micronutrient and nutritional deficiencies associated with GLP-1 receptor agonist therapy: a narrative review","volume":"16","author":"Urbina","year":"2026","journal-title":"Clin Obes"},{"key":"10.1016\/j.jhep.2026.08.028_bib77","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy weight loss maintenance with exercise, liraglutide, or both combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.08.028_bib78","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/oby.70164","article-title":"Joint TOS\/OMA\/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach","volume":"34","author":"Alexander","year":"2026","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jhep.2026.08.028_bib79","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S2213-8587(25)00395-X","article-title":"Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study","volume":"14","author":"Nguyen","year":"2026","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jhep.2026.08.028_bib80","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1001\/jama.2025.24288","article-title":"World Health Organization Guideline on the use and indications of glucagon-like peptide-1 therapies for the treatment of obesity in adults","volume":"335","author":"Celletti","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2026.08.028_bib81","series-title":"Rezdiffra [package insert]; West Conshohocken, PA","author":"Madrigal Pharmaceuticals, Inc.","year":"2024"},{"key":"10.1016\/j.jhep.2026.08.028_bib82","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.jhep.2019.08.008","article-title":"EASL Clinical Practice Guideline: occupational liver diseases","volume":"71","author":"European Association for the Study of the Liver","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.08.028_bib83","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/hep.32689","article-title":"AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury","volume":"77","author":"Fontana","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.08.028_bib84","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/oby.23673","article-title":"Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight\/obesity: STEP 5","volume":"31","author":"Wharton","year":"2023","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jhep.2026.08.028_bib85","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.08.028_bib86","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2026.08.028_bib87","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2026.08.028_bib88","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2026.08.028_bib89","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2026.08.028_bib90","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2026.08.028_bib91","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12933-026-03140-0","article-title":"CVOT summit report 2025: advances along the cardiovascular-kidney-metabolic disease continuum","volume":"25","author":"Schnell","year":"2026","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jhep.2026.08.028_bib92","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with Type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2026.08.028_bib93","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-026-04281-1","article-title":"Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial","volume":"32","author":"Meyh\u00f6fer","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2026.08.028_bib94","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2021-002517","article-title":"Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK","volume":"10","author":"Weiss","year":"2022","journal-title":"BMJ Open Diab Res Care"},{"key":"10.1016\/j.jhep.2026.08.028_bib95","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 receptor agonist discontinuation among patients with obesity and\/or Type 2 diabetes","volume":"7","author":"Do","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhep.2026.08.028_bib96","doi-asserted-by":"crossref","first-page":"6200","DOI":"10.1111\/dom.70004","article-title":"Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic","volume":"27","author":"Samuels","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2026.08.028_bib97","article-title":"Suboptimal therapeutic responses associated with semaglutide in type 2 diabetes and obesity: a meta-analysis of randomized controlled trials","volume":"7","author":"Ko","year":"2026","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jhep.2026.08.028_bib98","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1038\/s41591-025-03799-0","article-title":"Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"31","author":"Jara","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2026.08.028_bib99","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1136\/gutjnl-2024-334591","article-title":"Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies","volume":"74","author":"Celsa","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2026.08.028_bib100","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(26)00305-3","article-title":"Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial","volume":"407","author":"Klausen","year":"2026","journal-title":"The Lancet"},{"key":"10.1016\/j.jhep.2026.08.028_bib101","doi-asserted-by":"crossref","first-page":"697","DOI":"10.14309\/ajg.0000000000003585","article-title":"Association of glucagon-like peptide-1 receptor agonists with liver-related outcomes and all-cause mortality in patients with harmful alcohol use: a target trial emulation study","volume":"121","author":"John","year":"2026","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2026.08.028_bib102","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/dom.14890","article-title":"Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses","volume":"25","author":"Kosiborod","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2026.08.028_bib103","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jhep.2026.08.028_bib104","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1056\/NEJMe2314365","article-title":"Selective agonists of thyroid hormone receptor beta for the treatment of NASH","volume":"390","author":"Cusi","year":"2024","journal-title":"N Engl J Med"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826028771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826028771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:24:25Z","timestamp":1793103865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826028771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":104,"alternative-id":["S0168827826028771"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.08.028","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}